Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Feb 13, 6:25 AMASML shares rise about 1.8% after Applied Materials’ stronger‑than‑expected revenue and profit forecast lifts chip‑equipment stocks.

Peers: AMAT LRCX KLAC TER TSM NVDA AVGO INTC AMD MU

| Held by: QQQ SMH SOXX QQQM SOXL JEPQ DFAI DIHP AVDE DFIC

Index	NDX	P/E	50.34	EPS (ttm)	27.94	Insider Own	0.05%	Shs Outstand	387.60M	Perf Week	-0.45%
Market Cap	545.20B	Forward P/E	31.09	EPS next Y	45.24	Insider Trans	0.00%	Shs Float	387.40M	Perf Month	11.31%
Enterprise Value	532.74B	PEG	1.45	EPS next Q	7.72	Inst Own	17.54%	Short Float	0.31%	Perf Quarter	35.60%
Income	10.86B	P/S	14.75	EPS this Y	19.04%	Inst Trans	5.47%	Short Ratio	0.71	Perf Half Y	86.25%
Sales	36.96B	P/B	24.43	EPS next Y	28.66%	ROA	19.80%	Short Interest	1.21M	Perf YTD	31.48%
Book/sh	57.58	P/C	34.85	EPS next 5Y	21.40%	ROE	51.52%	52W High	1493.47 -5.82%	Perf Year	81.03%
Cash/sh	40.37	P/FCF	43.41	EPS past 3/5Y	23.38% 23.58%	ROIC	41.44%	52W Low	578.51 143.14%	Perf 3Y	110.34%
Dividend Est.	10.11 (0.72%)	EV/EBITDA	38.22	Sales past 3/5Y	18.33% 18.27%	Gross Margin	52.80%	Volatility	2.60% 3.49%	Perf 5Y	135.22%
Dividend TTM	7.71 (0.55%)	EV/Sales	14.41	EPS Y/Y TTM	34.44%	Oper. Margin	34.58%	ATR (14)	47.81	Perf 10Y	1614.54%
Dividend Ex-Date	Apr 27, 2026	Quick Ratio	0.79	Sales Y/Y TTM	21.00%	Profit Margin	29.39%	RSI (14)	57.95	Recom	1.61
Dividend Gr. 3/5Y	13.07% 21.83%	Current Ratio	1.26	EPS Q/Q	17.00%	SMA20	0.37%	Beta	1.89	Target Price	1649.33
Payout	26.78%	Debt/Eq	0.14	Sales Q/Q	14.48%	SMA50	13.17%	Rel Volume	0.73	Prev Close	1406.87
Employees	43520	LT Debt/Eq	0.14	Earnings	Jan 28 BMO	SMA200	48.81%	Avg Volume	1.71M	Price	1406.61
IPO	Mar 15, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.01% 3.77%	Trades		Volume	1,246,209	Change	-0.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-26	Upgrade	Barclays	Equal Weight → Overweight
Jan-15-26	Initiated	RBC Capital Mkts	Outperform
Jan-05-26	Upgrade	Bernstein	Mkt Perform → Outperform	$1528
Nov-07-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Oct-06-25	Downgrade	New Street	Buy → Neutral
Sep-29-25	Upgrade	Mizuho	Neutral → Outperform
Sep-22-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-22-25	Upgrade	Erste Group	Hold → Buy
Sep-05-25	Upgrade	UBS	Neutral → Buy
Jul-24-25	Upgrade	New Street	Neutral → Buy
Jul-23-25	Downgrade	Erste Group	Buy → Hold
Jun-26-25	Downgrade	Jefferies	Buy → Hold
Jun-17-25	Initiated	Bernstein	Mkt Perform	$806
Jun-03-25	Downgrade	Barclays	Overweight → Equal Weight
Jan-30-25	Upgrade	DZ Bank	Hold → Buy
Dec-03-24	Resumed	Exane BNP Paribas	Outperform	$858
Sep-20-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-04-24	Downgrade	UBS	Buy → Neutral
Jul-30-24	Upgrade	Barclays	Equal Weight → Overweight
Apr-16-24	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Feb-14-26 09:30AM	These 'safer' chip stocks have boomed this year. Is it too late to buy in? (MarketWatch)
Feb-13-26 02:00PM	Tech Boom & Defense Backlogs: 2 Sectors Poised to Outperform in 2026 (Zacks)
10:16AM	ASML Climbs 11% in a Month: Time to Buy, Sell or Hold the Stock? (Zacks)
08:58AM	Applied Materials Stock Rises. Its Another Winner from the Memory-Chip Boom. (Barrons.com)
04:56AM	Applied Materials jumps as AI demand drives chipmaking tool orders (Reuters)
03:56AM	Loading…
03:56AM	Applied Materials Stock Rises After Earnings. Why It's a Shelter From AI Fears. (Barrons.com)
Feb-12-26 01:50PM	Qnity Electronics Stock Sees IBD RS Rating Climb To 79 (Investor's Business Daily)
Feb-11-26 01:47PM	Chip Equipment Maker Axcelis Technologies Gets RS Rating Lift (Investor's Business Daily)
12:45PM	Here is Why Growth Investors Should Buy ASML (ASML) Now (Zacks)
11:57AM	KLA Shares Drop 15% Post Q2 Earnings: Should You Buy on the Dip? (Zacks)
08:47AM	Alibaba, Marvell, ASML And SoFi Get 2X ETF Boost With Direxion's Latest Launch (Benzinga)
08:44AM	4 Stocks to Boost Your Portfolio on Solid Semiconductor Sales Growth (Zacks)
07:49AM	Europe's OpenAI Rival Mistral Bets $1.4 Billion On Swedish AI Infrastructure Buildout (Benzinga)
06:12AM	French AI firm Mistral to build data centres in Sweden (AFP)
Feb-10-26 05:01PM	Global Markets Crushed US Stocks In 2025 - ETFs Investors Are Watching Now (Benzinga)
04:32PM	Loading…
04:32PM	Broader Market Falls Ahead of Wednesdays US Jobs Report (Barchart)
02:07PM	Attention Catholics: Theres a New Index Fund For Your Values (Moby)
11:51AM	Vatican Bank launches 'Catholic-based' stock indices (Euronews)
11:36AM	AMAT Climbs 8% in a Month: Time to Buy, Sell or Hold the Stock? (Zacks)
09:02AM	International ETFs to Watch as Foreign Stock Markets Beat the US (Zacks)
Feb-09-26 04:34PM	Stocks Settle Higher on Strength in Tech (Barchart)
09:58AM	AMAT to Post Q1 Earnings: Time to Buy, Sell or Hold the Stock? (Zacks)
09:35AM	ASML (ASML) Recently Broke Out Above the 20-Day Moving Average (Zacks)
09:30AM	Wall Street Bulls Look Optimistic About ASML (ASML): Should You Buy? (Zacks)
08:00AM	ASML reports transactions under its current share buyback program (GlobeNewswire)
06:17AM	Imec opens 2.5 billion euros chip pilot line as Europe looks to strengthen AI hand (Reuters)
Feb-06-26 04:00PM	Top Funds Like Google But Go Bonkers For These Three Stocks (Investor's Business Daily)
08:23AM	Genpact Q4 Earnings Call Highlights (MarketBeat)
03:07AM	General Motors CFO Flags $3$4B Tariff Hit, Margin Rebound and EV Reset at Conference (MarketBeat)
Feb-05-26 12:00PM	ASML (ASML) is a Great Momentum Stock: Should You Buy? (Zacks)
10:29AM	Loading…
10:29AM	The Euro Keeps Rising. The U.S. Is Helping. (Barrons.com)
09:00AM	ASML Holding N.V. (ASML) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:25AM	TSMC Expands AI Chip Production to Japan (24/7 Wall St.)
07:37AM	GM, TRV & ASML: 3 Industry Giants Boosting Buybacks in 2026 (MarketBeat)
Feb-04-26 11:12AM	Rotation out of Tech Stocks Weighs on the Broader Market (Barchart)
08:37AM	Broadcom Is 'Uncle Sam Of AI,' Says Futurum Equities As It Lists 15 Non-Mag7 AI Disruptors (Benzinga)
08:00AM	Top-Performing ETF Stories of January: Winning Investing Areas (Zacks)
06:12AM	Samsung Arms Its Advanced Chip Push With Invisix Investment (Benzinga)
Feb-03-26 09:50PM	Don't Know Which AI Stock To Buy? Here's the Easiest Way To Play the Once-in-a-Generation Tech Boom. (Motley Fool)
04:26PM	Stocks Tumble on AI Disruption Fears (Barchart)
11:37AM	The Zacks Analyst Blog Highlights Alphabet, Amazon, ASML, Micron and Lam Research (Zacks)
08:35AM	Why Half the Worlds Market Value Sits Outside Your Portfolio Right Now (24/7 Wall St.)
12:20AM	Prediction: ASML Could Be One of the Best Semiconductor Stocks of 2026 (Motley Fool)
Feb-02-26 03:58PM	These software stocks could rise as much as 75%. But is now the time to buy? (MarketWatch)
10:15AM	Best Momentum Stocks to Buy for February 2nd (Zacks)
09:51AM	Bernstein Raises PT on ASML Holding as the Company Updates 2026 Outlook (Insider Monkey)
09:10AM	ASML Holding N.V. (ASML) Investors Press Executives on the Outlook Despite the Bookings Success (Insider Monkey)
09:05AM	ASML's Secret Weapon for 2026: Why Memory Chips Could Drive Massive Growth (Motley Fool)
08:00AM	ASML reports transactions under its current share buyback program (GlobeNewswire)
Feb-01-26 01:25PM	Bernstein Doubles Down on ASML Holding (ASML) as Memory and EUV Momentum Builds (Insider Monkey)
10:35AM	Is It Time to Buy ASML as Orders Surge? (Motley Fool)
04:30AM	5 big analyst AI moves: Apple faces further downside; ASML, AMAT upgraded (Investing.com)
Jan-31-26 09:01PM	The Behind-the-Scenes Monopoly Powering the Tech Industry (Motley Fool)
11:53AM	ASML Holding (ASML) is the Best There Is, Says Jim Cramer (Insider Monkey)
06:35AM	Could This Be the Next Artificial Intelligence (AI) Stock to Join the Trillion-Dollar Club? (Motley Fool)
Jan-30-26 06:13PM	ASML Earnings Clear the Way for More Gains in 2026 (MarketBeat)
02:36PM	Micron Stock Hits Record High -- Insiders Are Selling (GuruFocus.com)
12:07PM	Why KLA's Stock Crashed Today (Motley Fool)
07:02AM	TD Cowen Raises ASML Holding (ASML) Price Target to 1,500 on Strong EUV Bookings (Insider Monkey)
06:25AM	Intel Just Made a Big Bet on ASML's Next-Gen Technology. Here's Why It Matters in 2026. (Motley Fool)
Jan-29-26 03:45PM	1 ASML Chart That Every Chip Stock Investor Needs To See (Motley Fool)
02:25PM	3 Reasons ASML Stock Could Soar in 2026 (Motley Fool)
12:43PM	Jim Cramer Says ASML and Peers "Still Got More Room to Run" (Insider Monkey)
11:40AM	ASML Holding Q4 Earnings Miss Expectations, Revenues Rise Y/Y (Zacks)
10:55AM	Analysis-Is chip giant ASML about to hit a ceiling, or break through it? (Reuters)
07:42AM	Bernstein Bullish on ASML Holding N.V. (ASML) Amid Strong China-Related DUV Demand (Insider Monkey)
07:40AM	Norway's Wealth Fund Trims Holdings of Nvidia, Other U.S. Tech Stocks (The Wall Street Journal)
07:40AM	Norway's Sovereign-Wealth Fund Trims Some U.S. Tech Stocks (The Wall Street Journal)
07:17AM	ASML rises as Barclays lifts rating after results, sees scope for more upside (Investing.com)
07:04AM	Chip Stocks Rally on ASML Blockbuster Bookings (GuruFocus.com)
06:52AM	S&P 500 Hits 7,000 for the First Time Ever (GuruFocus.com)
02:47AM	From Meta to Samsung, Tech Firms Unleash AI Spending Spree (Bloomberg)
Jan-28-26 04:32PM	Stocks Finish Mixed as Fed Keeps Interest Rates Steady (Barchart)
04:13PM	Amazon to Cut 16,000 Jobs. Whats Behind Its Largest Ever Corporate Layoffs. (Barrons.com)
04:08PM	Intel, Micron, These Other Chip Stocks Are Rallying. Thank Texas Instruments and ASML. (Barrons.com)
04:03PM	Intel's Stock Soars as Client Rumors Swirl: Could Nvidia and Apple Deals Be on the Way? (Investopedia)
04:02PM	Chip Makers Point to Accelerating Demand. Its a Big Deal. (Barrons.com)
04:01PM	ASML Holding NV (ASML) Q4 2025 Earnings Call Highlights: Strong Net Sales and Robust Backlog ... (GuruFocus.com)
04:01PM	Stock market today: S&P 500 slips from record as Fed stands pat, Nasdaq rises before Big Tech earnings flurry (Yahoo Finance)
04:00PM	ASML Stock Falls Despite Strong Sales Forecast For 2026 (Investor's Business Daily)
02:53PM	BofA Sees Limited China Risk for ASML Holding N.V. (ASML), Maintains Top Pick Rating (Insider Monkey)
02:50PM	Stock market today: Dow, S&P 500, Nasdaq waver as Fed holds rates steady, Big Tech earnings loom (Yahoo Finance)
02:00PM	Stock market today: S&P 500 briefly touches 7,000 mark, Fed keeps rates unchanged (Yahoo Finance)
01:49PM	Stock market today: S&P 500 touches 7,000 mark as Wall Street braces for Fed decision, Big Tech earnings (Yahoo Finance)
01:01PM	Gold Rallies To $5,300, Memory Stocks Go Wild: What's Moving Markets Wednesday? (Benzinga)
12:59PM	ASML Investors Press Executives on Outlook Despite Bookings Beat (Bloomberg)
12:40PM	ASML's CEO Says AI Demand Is Accelerating. Is the Stock a Buy for 2026? (Motley Fool)
11:42AM	Earnings in Focus Wednesday: Seagate, AT&T, Starbucks (The Wall Street Journal)
11:20AM	Chip-Machine Giant ASML Logs Record Orders as AI Spending Booms (The Wall Street Journal)
11:18AM	ASML Q4 Results Reveal 'Insane' $46B Backlog (Benzinga)
11:15AM	Stocks Supported by Solid Tech Earnings (Barchart)
11:15AM	Stocks Mixed After the Fed Pauses Rate Cuts (Barchart)
11:07AM	ASML Reports Record Orders, Launches $12 Billion Buyback (GuruFocus.com)
10:37AM	ASML Reports Record Orders Amid AI Chip Boom. The Stock Is Dropping. (Barrons.com)
10:21AM	The AI infrastructure boom shows no sign of slowing down (TechCrunch)
10:21AM	S&P 500 breaches 7,000 as tech giants Microsoft and Meta prep earnings (Investing.com)
10:06AM	ASML Stock Wavers Despite Strong Sales Forecast For 2026 (Investor's Business Daily)
09:48AM	ASML Confirms AI-Driven Strength With Record Orders (GuruFocus.com)
09:38AM	Stock market today: S&P 500 breaches 7,000 mark Wall Street braces for Fed decision, Big Tech earnings (Yahoo Finance)
09:37AM	Chip Stocks Get Another Boost From ASML Earnings (The Wall Street Journal)

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

Open in Screener

DYN

Dyne Therapeutics Inc

Feb 13 • 04:00PM ET

15.54

-0.46 -2.88 %

Healthcare • Biotechnology • USA • NASD

DYN Dyne Therapeutics Inc daily Stock Chart

Peers: BIIB VRTX CRSP ALNY BMRN RARE NTLA SRPT EDIT BLUE

| Held by: VTI XBI IWM VB VXF VBR IBB VTWO IWN SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.66	Insider Own	26.51%	Shs Outstand	142.61M	Perf Week	-7.50%
Market Cap	2.51B	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-0.03%	Shs Float	118.92M	Perf Month	-10.95%
Enterprise Value	1.84B	PEG	-	EPS next Q	-0.76	Inst Own	87.87%	Short Float	16.14%	Perf Quarter	-16.50%
Income	-423.80M	P/S	-	EPS this Y	-3.91%	Inst Trans	32.82%	Short Ratio	7.70	Perf Half Y	24.32%
Sales	0.00M	P/B	3.20	EPS next Y	7.20%	ROA	-51.81%	Short Interest	19.19M	Perf YTD	-20.55%
Book/sh	4.85	P/C	3.18	EPS next 5Y	4.87%	ROE	-60.66%	52W High	25.00 -37.84%	Perf Year	10.60%
Cash/sh	4.89	P/FCF	-	EPS past 3/5Y	-4.75% -59.45%	ROIC	-52.50%	52W Low	6.36 144.34%	Perf 3Y	16.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.57% 5.92%	Perf 5Y	-16.50%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-2.75%	Oper. Margin	-	ATR (14)	1.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.47	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	34.23	Recom	1.31
Dividend Gr. 3/5Y	- -	Current Ratio	13.47	EPS Q/Q	20.87%	SMA20	-10.70%	Beta	1.34	Target Price	39.12
Payout	-	Debt/Eq	0.17	Sales Q/Q	-	SMA50	-15.82%	Rel Volume	0.36	Prev Close	16.00
Employees	191	LT Debt/Eq	0.17	Earnings	Nov 05 AMC	SMA200	4.58%	Avg Volume	2.49M	Price	15.54
IPO	Sep 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.21% -	Trades		Volume	898,857	Change	-2.88%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform	$40
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy	$35
Jun-24-25	Initiated	Bernstein	Mkt Perform	$13
Jun-11-25	Resumed	Raymond James	Outperform	$37
Jun-02-25	Resumed	Oppenheimer	Outperform	$34
May-29-25	Initiated	Evercore ISI	Outperform	$46
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Dec-13-24	Initiated	Robert W. Baird	Outperform	$46
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$45
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral	$43 → $35
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15

Show Previous Ratings

Jan-27-26 09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-20-26 07:30AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-15-26 11:35AM	Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) (Insider Monkey) -5.90%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 07:30AM	Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.01%
07:30AM	Loading…
Dec-23-25 07:30AM	Dyne Therapeutics Appoints Vikram Karnani to Board of Directors (GlobeNewswire)
Dec-22-25 06:50AM	Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) (Insider Monkey)
Dec-11-25 04:05PM	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
07:44AM	Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial (Insider Monkey)
Dec-10-25 06:20PM	Why Dyne Therapeutics Stock Was a Big Winner on Wednesday (Motley Fool) +6.78%
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
Dec-09-25 09:42PM	Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock (GlobeNewswire) -16.94%
06:42PM	Why Dyne Therapeutics Stock Tanked on Tuesday (Motley Fool)
04:54PM	Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More (Motley Fool)
02:22PM	Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate (Insider Monkey)
01:34PM	Loading…
01:34PM	Dyne to seek accelerated approval of DMD drug on Phase I/II data (Clinical Trials Arena)
Dec-08-25 04:02PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +9.47%
03:07PM	Why Dyne Therapeutics Stock Was Blasting Higher Today (Motley Fool)
06:30AM	Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 11:00AM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET (GlobeNewswire)
Nov-30-25 12:26AM	Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release (Insider Monkey)
Nov-21-25 03:43PM	Why Dyne Therapeutics Stock Was Crushing it This Week (Motley Fool) +5.27%
Nov-05-25 04:10PM	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -12.89%
Nov-03-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +6.78%
Oct-28-25 05:24AM	Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger (Insider Monkey)
Oct-27-25 06:17PM	Why Dyne Therapeutics Stock Crushed the Market on Monday (Motley Fool) +41.18%
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:39AM	Loading…
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
Oct-16-25 04:33PM	Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year (Insider Monkey)
Oct-06-25 06:01PM	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +10.28%
Oct-04-25 04:54PM	Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data (Insider Monkey)
Oct-02-25 04:05PM	Dyne Therapeutics Appoints Brian Posner to its Board of Directors (GlobeNewswire)
Sep-29-25 08:35AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire) -5.93%
Sep-10-25 12:20AM	Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating (Insider Monkey)
Aug-27-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:13AM	Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT (Insider Monkey)
Aug-17-25 11:41PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy (Insider Monkey)
Aug-06-25 12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com) +10.70%
Aug-04-25 07:30AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Jul-31-25 09:55AM	Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 04:10PM	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.43%
Jul-16-25 07:00AM	Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer (Business Wire) +12.68%
Jul-11-25 11:27AM	RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT (Insider Monkey)
Jul-02-25 04:01PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-25 09:45PM	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock (GlobeNewswire) -8.82%
04:05PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital (GlobeNewswire)
Jun-24-25 12:46PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101 (Insider Monkey)
Jun-18-25 09:45AM	Dyne at attractive entry point following pullback, says Chardan (TipRanks)
Jun-17-25 07:00AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting (GlobeNewswire) -21.42%
Jun-16-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET (GlobeNewswire)
Jun-05-25 07:30AM	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress (GlobeNewswire)
May-08-25 07:30AM	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +20.16%
Apr-25-25 05:05AM	EC grants orphan drug designation to Dyne Therapeutics DMD therapy (Pharmaceutical Technology)
Apr-24-25 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +14.20% +6.22%
Apr-15-25 07:30AM	Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments (GlobeNewswire) +5.09%
Apr-14-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -11.76%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
04:19PM	Dyne Therapeutics appoints Erick Lucera as CFO (SeekingAlpha)
04:10PM	Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer (GlobeNewswire)
Mar-16-25 07:00PM	Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months (GlobeNewswire)
Mar-12-25 03:05PM	Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks (Benzinga)
01:12PM	BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating (GuruFocus.com)
Mar-11-25 07:30AM	Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Feb-27-25 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-14-25 04:05PM	Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-13-25 09:35AM	After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) (Zacks)
Feb-06-25 09:39AM	Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey) +6.89%
Feb-03-25 07:30AM	Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-25 09:35AM	Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround (Zacks)
Jan-21-25 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-10-25 06:30AM	Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 (GlobeNewswire) -31.15%
Jan-09-25 07:30AM	Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET (GlobeNewswire) -31.15%
Nov-22-24 06:43AM	Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-12-24 07:30AM	Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:15PM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-09-24 07:30AM	Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases (GlobeNewswire)
Oct-07-24 05:32PM	Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now (Insider Monkey)
Sep-23-24 08:56AM	Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -5.36%
Sep-04-24 09:10AM	Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes (Investor's Business Daily) +5.70%
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 12:37PM	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy (Benzinga) -30.70%
06:31AM	Dyne Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
06:30AM	Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts (GlobeNewswire)
Aug-29-24 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-24 10:52PM	DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
05:10PM	Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-29-24 08:50AM	Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why (Zacks)
Jul-18-24 12:00PM	What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now? (Zacks)
Jul-12-24 08:50AM	Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-24-24 07:30AM	Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease (GlobeNewswire)
Jun-13-24 04:40PM	Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress (GlobeNewswire)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kerr Douglas	Officer	Dec 05 '25	Proposed Sale	20.72	880	18,231		Dec 05 04:56 PM
Cox John	Officer	Dec 05 '25	Proposed Sale	20.72	2,662	55,150		Dec 05 04:55 PM
Cox John	CEO & President	Dec 05 '25	Sale	20.72	2,662	55,157	196,877	Dec 05 04:11 PM
Kerr Douglas	Chief Medical Officer	Dec 05 '25	Sale	20.72	880	18,234	87,510	Dec 05 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Dec 05 '25	Sale	20.72	144	2,984	94,729	Dec 05 04:08 PM
Cox John	CEO & President	Sep 05 '25	Sale	13.41	2,640	35,402	199,539	Sep 09 04:31 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 04 '25	Sale	13.27	894	11,863	95,017	Sep 08 04:06 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 05 '25	Sale	13.41	144	1,931	94,873	Sep 08 04:06 PM
Kerr Douglas	Chief Medical Officer	Sep 04 '25	Sale	13.27	3,552	47,135	89,263	Sep 08 04:03 PM
Kerr Douglas	Chief Medical Officer	Sep 05 '25	Sale	13.41	873	11,707	88,390	Sep 08 04:03 PM
Cox John	Officer	Sep 05 '25	Proposed Sale	13.41	2,640	35,404		Sep 05 04:14 PM
Kerr Douglas	Officer	Sep 04 '25	Proposed Sale	13.27	4,552	60,402		Sep 04 04:45 PM
Cox John	CEO & President	Jul 14 '25	Buy	9.11	100,000	911,000	242,179	Jul 15 05:11 PM
Scalzo Richard William	Officer	Jun 11 '25	Proposed Sale	14.75	1,330	19,619		Jun 11 04:30 PM
Beskrovnaya Oxana	Officer	Jun 11 '25	Proposed Sale	14.75	2,132	31,449		Jun 11 04:29 PM
Cox John	CEO & President	Jun 05 '25	Sale	13.35	4,060	54,201	142,179	Jun 06 04:07 PM
Kerr Douglas	Chief Medical Officer	Jun 05 '25	Sale	13.35	1,342	17,916	92,815	Jun 06 04:05 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Jun 05 '25	Sale	13.35	146	1,949	95,911	Jun 06 04:03 PM
Kerr Douglas	Officer	Jun 05 '25	Proposed Sale	13.35	1,342	17,911		Jun 05 04:13 PM
Cox John	Officer	Jun 05 '25	Proposed Sale	13.35	4,060	54,186		Jun 05 04:11 PM
Scalzo Richard William	Officer	Jun 05 '25	Proposed Sale	13.35	914	12,198		Jun 05 04:09 PM
Beskrovnaya Oxana	Officer	Jun 05 '25	Proposed Sale	13.35	1,093	14,587		Jun 05 04:07 PM
Scalzo Richard William	Officer	May 16 '25	Proposed Sale	11.82	2,479	29,313		May 16 04:10 PM
Beskrovnaya Oxana	Officer	May 16 '25	Proposed Sale	11.82	2,589	30,614		May 16 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Mar 13 '25	Sale	12.12	143	1,733	96,057	Mar 13 04:13 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 11 '25	Sale	11.38	1,343	15,283	122,330	Mar 13 04:08 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11 '25	Sale	11.38	2,153	24,501	195,840	Mar 13 04:08 PM
Beskrovnaya Oxana	Officer	Mar 11 '25	Proposed Sale	11.38	2,153	24,493		Mar 11 04:09 PM
Scalzo Richard William	Officer	Mar 11 '25	Proposed Sale	11.38	1,343	15,278		Mar 11 04:08 PM
Kerr Douglas	Chief Medical Officer	Mar 05 '25	Sale	11.83	1,343	15,888	94,157	Mar 07 04:08 PM
Cox John	CEO & President	Mar 05 '25	Sale	11.83	4,061	48,042	146,239	Mar 07 04:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 05 '25	Sale	11.83	917	10,848	123,673	Mar 07 04:06 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 05 '25	Sale	11.83	1,094	12,942	197,993	Mar 07 04:04 PM
Kerr Douglas	Officer	Mar 05 '25	Proposed Sale	11.89	1,343	15,968		Mar 05 04:10 PM
Cox John	Officer	Mar 05 '25	Proposed Sale	11.89	4,067	48,356		Mar 05 04:09 PM
Beskrovnaya Oxana	Officer	Mar 05 '25	Proposed Sale	11.89	1,094	13,007		Mar 05 04:08 PM
Scalzo Richard William	Officer	Mar 05 '25	Proposed Sale	11.89	915	10,879		Mar 05 04:07 PM
Beskrovnaya Oxana	Chief Scientific Officer	Feb 18 '25	Sale	13.95	2,598	36,242	199,087	Feb 25 05:09 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 18 '25	Sale	13.95	2,488	34,708	124,590	Feb 18 05:09 PM
Scalzo Richard William	Officer	Feb 18 '25	Proposed Sale	13.91	2,488	34,608		Feb 18 04:15 PM
Beskrovnaya Oxana	Officer	Feb 18 '25	Proposed Sale	13.91	2,598	36,138		Feb 18 04:14 PM

ASML

ASML Holding NV

DYN

Dyne Therapeutics Inc

Upgrade your FINVIZ experience